Aurinia Pharmaceuticals (NASDAQ:AUPH) CEO Kevin Tang Buys 343,620 Shares

Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) (TSE:AUP) CEO Kevin Tang purchased 343,620 shares of the firm’s stock in a transaction that occurred on Monday, June 1st. The stock was bought at an average price of $15.28 per share, for a total transaction of $5,250,513.60. Following the purchase, the chief executive officer owned 12,838,101 shares in the company, valued at $196,166,183.28. The trade was a 2.75% increase in their position. The purchase was disclosed in a document filed with the SEC, which is accessible through this link.

Kevin Tang also recently made the following trade(s):

• On Tuesday, June 2nd, Kevin Tang purchased 206,005 shares of Aurinia Pharmaceuticals stock. The shares were purchased at an average price of $15.28 per share, for a total transaction of $3,147,756.40.
• On Friday, May 29th, Kevin Tang acquired 264,981 shares of Aurinia Pharmaceuticals stock. The stock was bought at an average cost of $15.31 per share, with a total value of $4,056,859.11.

Aurinia Pharmaceuticals Price Performance

AUPH stock opened at $15.39 on Wednesday. The company has a fifty day moving average price of $15.51 and a 200-day moving average price of $15.25. The company has a market capitalization of $1.98 billion, a P/E ratio of 7.09 and a beta of 1.41. Aurinia Pharmaceuticals Inc has a 52-week low of $7.28 and a 52-week high of $16.88. The company has a debt-to-equity ratio of 0.08, a quick ratio of 5.01 and a current ratio of 5.55.

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last posted its quarterly earnings data on Thursday, May 7th. The biotechnology company reported $0.25 earnings per share for the quarter, topping the consensus estimate of $0.18 by $0.07. The company had revenue of $77.71 million during the quarter, compared to analysts’ expectations of $76.98 million. Aurinia Pharmaceuticals had a net margin of 99.97% and a return on equity of 26.62%. As a group, equities analysts expect that Aurinia Pharmaceuticals Inc will post 0.82 EPS for the current year.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings cut shares of Aurinia Pharmaceuticals from a “buy (b-)” rating to a “hold (c+)” rating in a report on Friday, May 15th. Two investment analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $17.25.

Institutional Trading of Aurinia Pharmaceuticals

Several hedge funds have recently added to or reduced their stakes in the stock. Mirae Asset Global Investments Co. Ltd. raised its position in Aurinia Pharmaceuticals by 25.9% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 6,407 shares of the biotechnology company’s stock worth $102,000 after acquiring an additional 1,318 shares during the period. MML Investors Services LLC raised its position in Aurinia Pharmaceuticals by 12.7% in the fourth quarter. MML Investors Services LLC now owns 15,643 shares of the biotechnology company’s stock worth $250,000 after acquiring an additional 1,765 shares during the period. First Trust Advisors LP increased its stake in shares of Aurinia Pharmaceuticals by 15.5% in the first quarter. First Trust Advisors LP now owns 14,065 shares of the biotechnology company’s stock worth $208,000 after purchasing an additional 1,883 shares in the last quarter. BOK Financial Private Wealth Inc. purchased a new position in shares of Aurinia Pharmaceuticals in the fourth quarter worth about $32,000. Finally, Concurrent Investment Advisors LLC increased its stake in shares of Aurinia Pharmaceuticals by 7.8% in the fourth quarter. Concurrent Investment Advisors LLC now owns 30,270 shares of the biotechnology company’s stock worth $483,000 after purchasing an additional 2,200 shares in the last quarter. Institutional investors own 36.83% of the company’s stock.

Aurinia Pharmaceuticals Company Profile

Aurinia Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company focused on developing and commercializing therapies for autoimmune diseases. The company’s proprietary molecule, voclosporin, is designed to selectively inhibit calcineurin and reduce inflammation associated with autoimmune responses. Aurinia operates research and development facilities in Canada and the United States, leveraging collaborations with academic institutions and contract research organizations to advance its clinical pipeline.

The company’s lead product, voclosporin (marketed as LUPKYNIS), received approval from the U.S.